266 related articles for article (PubMed ID: 25273395)
1. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.
Fukuhara N; Horiguchi K; Nishioka H; Suzuki H; Takeshita A; Takeuchi Y; Inoshita N; Yamada S
Endocr J; 2015; 62(1):21-7. PubMed ID: 25273395
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
[TBL] [Abstract][Full Text] [Related]
3. Preoperative long-acting octreotide treatment for invasive thyrotropin-secreting pituitary macroadenoma after previous radioiodine thyroid ablation.
Gruszka A; Zielinski GM; Kunert-Radek J
J Clin Neurosci; 2014 Feb; 21(2):340-2. PubMed ID: 23958483
[TBL] [Abstract][Full Text] [Related]
4. Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide.
Iglesias P; Díez JJ
J Endocrinol Invest; 1998 Dec; 21(11):775-8. PubMed ID: 9972679
[TBL] [Abstract][Full Text] [Related]
5. Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.
Yin J; Su CB; Xu ZQ; Yang Y; Ma WB; Tao W; Yang Z; Xia XW
Chin Med Sci J; 2005 Mar; 20(1):23-6. PubMed ID: 15844307
[TBL] [Abstract][Full Text] [Related]
6. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
7. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
[TBL] [Abstract][Full Text] [Related]
9. [Octreotide in the diagnosis and treatment of pituitary thyrotropin-secreting adenoma].
Chen S; Li M; Lian XL; Zeng ZP; Dai WX; Li F; Yu W; Wang RZ
Zhonghua Nei Ke Za Zhi; 2006 Nov; 45(11):910-3. PubMed ID: 17313878
[TBL] [Abstract][Full Text] [Related]
10. Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge.
Nguyen HD; Galitz MS; Mai VQ; Clyde PW; Glister BC; Shakir MK
Thyroid; 2010 Jan; 20(1):99-103. PubMed ID: 20067380
[TBL] [Abstract][Full Text] [Related]
11. Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage.
Oshino S; Saitoh Y; Kasayama S; Arita N; Ohnishi T; Kohara H; Izumoto S; Yoshimine T
Endocr J; 2006 Feb; 53(1):125-32. PubMed ID: 16543682
[TBL] [Abstract][Full Text] [Related]
12. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
Teramoto A; Sanno N; Tahara S; Osamura YR
Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
[TBL] [Abstract][Full Text] [Related]
13. Management of a pregnant woman with thyrotropinoma: a case report and review of the literature.
Perdomo CM; Árabe JA; Idoate MÁ; Galofré JC
Gynecol Endocrinol; 2017 Mar; 33(3):188-192. PubMed ID: 27910710
[TBL] [Abstract][Full Text] [Related]
14. Thyrotropin secreting pituitary adenoma effectively treated with octreotide.
Fukuda T; Yokoyama N; Tamai M; Imaizumi M; Kimura H; Tominaga T; Ashizawa K; Kiriyama T; Yoshimine H; Ohishi K; Eguchi K
Intern Med; 1998 Dec; 37(12):1027-30. PubMed ID: 9932634
[TBL] [Abstract][Full Text] [Related]
15. Reduction in size of a thyrotropin- and gonadotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
Sy RA; Bernstein R; Chynn KY; Kourides IA
J Clin Endocrinol Metab; 1992 Mar; 74(3):690-4. PubMed ID: 1740506
[TBL] [Abstract][Full Text] [Related]
16. Hyperthyroidism caused by an ectopic thyrotropin-secreting tumor of the nasopharynx: a case report and review of the literature.
Tong A; Xia W; Qi F; Jin Z; Yang D; Zhang Z; Li F; Xing X; Lian X
Thyroid; 2013 Sep; 23(9):1172-7. PubMed ID: 23402621
[TBL] [Abstract][Full Text] [Related]
17. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
18. Thyroid storm induced by TSH-secreting pituitary adenoma: a case report.
Fujio S; Ashari ; Habu M; Yamahata H; Moinuddin FM; Bohara M; Arimura H; Nishijima Y; Arita K
Endocr J; 2014; 61(11):1131-6. PubMed ID: 25132171
[TBL] [Abstract][Full Text] [Related]
19. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
